These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37776474)

  • 1. Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review.
    Drysdale M; Gibbons DC; Singh M; Rolland C; Lavoie L; Skingsley A; Lloyd EJ
    Infection; 2024 Feb; 52(1):1-17. PubMed ID: 37776474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review.
    Drysdale M; Berktas M; Gibbons DC; Rolland C; Lavoie L; Lloyd EJ
    Infection; 2024 Oct; 52(5):1839-1861. PubMed ID: 38602623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study.
    Lo CKL; Lo CKF; Komorowski AS; Leung V; Matic N; McKenna S; Perez-Patrigeon S; Sheth PM; Lowe CF; Chagla Z; Bai AD
    BMC Res Notes; 2024 Jan; 17(1):37. PubMed ID: 38267971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.
    Patel V; Levick B; Boult S; Gibbons DC; Drysdale M; Lloyd EJ; Singh M; Birch HJ
    BMC Infect Dis; 2024 Apr; 24(1):428. PubMed ID: 38649824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium.
    Drysdale M; Hautekiet T; Singh M; Hautekiet J; Ludikhuyze L; Patel V; Gibbons DC; De Roeck D; Colpaert K; Lloyd EJ; Van Braeckel E
    Acta Clin Belg; 2024 Jun; 79(3):174-183. PubMed ID: 39081095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections.
    Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y; Ito T
    Viruses; 2023 May; 15(6):. PubMed ID: 37376600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real world effectiveness of sotrovimab in preventing COVID-19-related hospitalisation or death in patients infected with Omicron BA.2.
    Behzad A; Mohamed A; Ali A; Niinuma S; Butler AE; Alqahtani M
    J Infect Public Health; 2024 Feb; 17(2):315-320. PubMed ID: 38160562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase.
    Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Molina KC; Peers JL; Russell S; Wynia MK; Ginde AA
    Int J Infect Dis; 2023 Mar; 128():310-317. PubMed ID: 36229005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data.
    Russo A; Grimaldi P; Pisaturo M; Onorato L; Coppola N
    Front Immunol; 2024; 15():1295029. PubMed ID: 38352882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
    Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW
    Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge.
    Chesdachai S; Rivera CG; Cole KC; Teaford HR; Gonzalez Suarez ML; Larsen JJ; Ganesh R; Tulledge-Scheitel S; Razonable RR
    Sci Rep; 2024 Mar; 14(1):5430. PubMed ID: 38443438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C).
    Bell CF; Bobbili P; Desai R; Gibbons DC; Drysdale M; DerSarkissian M; Patel V; Birch HJ; Lloyd EJ; Zhang A; Duh MS;
    Clin Drug Investig; 2024 Mar; 44(3):183-198. PubMed ID: 38379107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
    Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
    J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar.
    Zaqout A; Almaslamani MA; Chemaitelly H; Hashim SA; Ittaman A; Alimam A; Rustom F; Daghfal J; Abukhattab M; AlMukdad S; Kaleeckal AH; Latif AN; Butt AA; Bertollini R; Al-Khal A; Omrani AS; Abu-Raddad LJ
    Int J Infect Dis; 2022 Nov; 124():96-103. PubMed ID: 36218031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
    Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
    EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic.
    Kikuchi K; Nangaku M; Ryuzaki M; Yamakawa T; Ota Y; Hanafusa N; Sakai K; Kanno Y; Ando R; Shinoda T; Wakino S; Nakamoto H; Takemoto Y; Akizawa T;
    Ther Apher Dial; 2023 Dec; 27(6):1064-1069. PubMed ID: 37395555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: a retrospective cohort study.
    Patel V; Yarwood MJ; Levick B; Gibbons DC; Drysdale M; Kerr W; Watkins JD; Young S; Pierce BF; Lloyd EJ; Birch HJ; Kamalati T; Brett SJ
    Curr Med Res Opin; 2024 Aug; 40(8):1323-1334. PubMed ID: 38975862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study.
    Drysdale M; Tibble H; Patel V; Gibbons DC; Lloyd EJ; Kerr W; Macdonald C; Birch HJ; Sheikh A
    BMC Infect Dis; 2024 Jul; 24(1):670. PubMed ID: 38965495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.
    Driouich JS; Bernadin O; Touret F; de Lamballerie X; Nougairède A
    Antiviral Res; 2023 Jul; 215():105638. PubMed ID: 37207822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Sotrovimab in Preventing COVID-19-Related Hospitalizations or Deaths Among US Veterans During Omicron BA.1.
    Young-Xu Y; Korves C; Zwain G; Satram S; Drysdale M; Reyes C; Cheng MM; Bonomo RA; Epstein L; Marconi VC; Ginde AA
    Open Forum Infect Dis; 2023 Dec; 10(12):ofad605. PubMed ID: 38152625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.